Ligne de temps
Elodie Chapeaublanc
Ingénieur(e) de Recherche
17 juil. 2023
27 juin 2023
publication
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
Lire plus22 mars 2023
publication
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.
Lire plus20 oct. 2022
publication
FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Lire plus01 janv. 2022
publication
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lire plus22 sept. 2021
publication
A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression.
Lire plus01 mars 2019
publication
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Lire plus23 janv. 2019
publication
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01.
Lire plus01 avr. 2018
publication
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
Lire plus28 mars 2018
07 sept. 2017
publication
IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
Lire plus26 juin 2015
13 nov. 2014
publication
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
Lire plus01 déc. 2013
01 nov. 2013
publication
PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.
Lire plus25 mai 2010
01 mai 2010
01 juil. 2009
publication